Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2017-01-01
2031-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Aims To determine the
* mechanisms behind cardioprotective effect of RBCs in myocardial infarction
* signaling behind cardiovascular injury induced by RBCs in T2D
Work plan RBCs collected from patients with myocardial infarction, patients with T2D and healthy controls are investigated in bioassays including isolated hearts of ischemia/reperfusion, endothelial function and cell cultures. Molecular mechanisms behind the effects of RBCs are identified with focus on the NO-sGC pathway in the RBCs.
This project unravels the RBC as a mediator of cardiovascular disease and has the potential to identify novel therapeutic strategies by targeting RBC signaling.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Tight Glycaemic Control in Acute Myocardial Infarction
NCT00237471
The Effect of Ischaemic-Reperfusion and Remote Ischaemic Preconditioning in Man - A Bradykinin Dependent Pathway
NCT00965393
Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen
NCT00320229
The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent Pathway
NCT00965120
Red Blood Cell Transfusion in Patients With Coronary Artery Disease (CAD)
NCT01504945
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Type 2 diabetes
Patients with type 2 diabetes
No interventions assigned to this group
Type 1 diabetes
Patients with type 1 diabetes
No interventions assigned to this group
Coronary artery disease/Myocardial infarction
Patients with acute coronary syndromes
No interventions assigned to this group
Healthy controls
Age- and gender-matched healthy subjects
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
25 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska University Hospital
OTHER
Karolinska Institutet
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John Pernow
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Pernow, MD
Role: PRINCIPAL_INVESTIGATOR
Karolinska Institutet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karolinska Institutet
Stockholm, Swsden, Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Pernow J, Yang J. Red blood cells: a new target to prevent cardiovascular disease? Eur Heart J. 2024 Oct 21;45(40):4249-4251. doi: 10.1093/eurheartj/ehae454. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-02534
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.